drugset / Trial / NCT06455072
Nituzumab Plus Serplulimab Combined With SBRT in Cervical Cancer
Phase 2
Unknown
37 enrolled
Fujian Cancer Hospital
Zhangzhou Municipal Hospital of Fujian Province · collab
NaSingle-groupOpen-labelTreatment
Summary
In recurrent advanced cervical cancer, patients were prone to drug resistance who have relapsed within prior platinum-based chemotherapy. However, immune checkpoint inhibitor's combination therapy has become a promising strategy for advanced cervical cancer. Epidermal Growth Factor Receptor (EGFR) is overexpressed in cervical cancer cells. Stereotactic radiotherapy (SBRT) can enhance the efficacy of immunotherapy.
Timeline
- Start
- 2023-02-01
- Primary completion
- 2025-01-31
- Completion
- 2025-01-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nituzumab | Monoclonal antibody | 400 mg | Intravenous |
| Subject | Serplulimab | Monoclonal antibody | 200 mg | Intravenous |